Neurotherapeutic Drug Delivery via Focused Ultrasound
- Summary
- Elisa E. Konofagou Ph.D..
- Technology Benefits
- Minimally invasive due to transient creation of small BB openingSafe and quick relative to techniques such as cranial surgeryNon-toxic compared to drug-based methods for BBB disruptionHighly localized for access to specific regions of the brainBased on FDA approved technologies: MRI, ultrasound and microbubblesPatent information:Patent Issued (US20090005711Patent Issued (WO/2007/035721Tech Ventures Reference: IR M09-025
- Technology Application
- Non-invasive administration of compounds that are currently only delivered via trans-cranial surgeryReviving drug candidates that were formerly dropped from developmentNeurological disorders with focal pathologies could be specifically targeted for drug delivery (e.g., Alzheimer's and Parkinson's)Treatment of psychiatric disordersAnesthetizing specific portions of the brain while leaving other portions unaffected
- Detailed Technology Description
- Elisa E. Konofagou Ph.D..
- *Abstract
-
None
- *Inquiry
- Satish RaoColumbia Technology VenturesTel: (212) 854-8444Email: TechTransfer@columbia.edu
- *IR
- M09-025
- *Principal Investigator
-
- *Publications
- Choi JJ, Wang S, Tung YS, Morrison B 3rd, Konofagou EE. "Molecules of various pharmacologicallyrelevant sizes can cross the ultrasound-induced blood-brain barrier opening in vivo". Ultrasound Med Biol.2010 Jan;36(1):58-67.
- *Web Links
- WIPO: US Pat App 20110295105
- Country/Region
- USA
For more information, please click Here
